Q3 2021 Financial Presentation2021-11-04 Report Presentation Webcast The Executive Managment in Ascelia Pharma presents a business update and the quarterly results InvestorGenväg till IR & Media IR & Media Key downloads QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submissionHalf-year report 2022: Strong results from Orviglance Food Effect StudyQuarterly Report Q1 2022: Strong Orviglance support from healthcare professionalsAscelia Pharma publishes Annual Report for 2021Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent
